NovoCure Limited (NVCR)
NovoCure Statistics
Share Statistics
NovoCure has 109.92M shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 109.92M |
| Shares Change (YoY) | 1.03% |
| Shares Change (QoQ) | -0.01% |
| Owned by Institutions (%) | 84.59% |
| Shares Floating | 98.34M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.87M, so 4.5% of the outstanding shares have been sold short.
| Short Interest | 4.87M |
| Short % of Shares Out | 4.5% |
| Short % of Float | 5.03% |
| Short Ratio (days to cover) | 4.65 |
Valuation Ratios
The PE ratio is -19.06 and the forward PE ratio is -15.09. NovoCure's PEG ratio is 0.95.
| PE Ratio | -19.06 |
| Forward PE | -15.09 |
| PS Ratio | 5.31 |
| Forward PS | 1.4 |
| PB Ratio | 8.92 |
| P/FCF Ratio | -46.42 |
| PEG Ratio | 0.95 |
Enterprise Valuation
NovoCure Limited has an Enterprise Value (EV) of 1.94B.
| EV / Earnings | -11.53 |
| EV / Sales | 3.21 |
| EV / EBITDA | -17.74 |
| EV / EBIT | -11.4 |
| EV / FCF | -28.08 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.46 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.26 |
| Total Debt / Capitalization | 20.54 |
| Cash Flow / Debt | -0.28 |
| Interest Coverage | 9.84 |
Financial Efficiency
Return on equity (ROE) is -0.47% and return on capital (ROIC) is -48.35%.
| Return on Equity (ROE) | -0.47% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -48.35% |
| Revenue Per Employee | $406,733.87 |
| Profits Per Employee | $-113,324.6 |
| Employee Count | 1,488 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.91 |
Taxes
| Income Tax | 37.47M |
| Effective Tax Rate | -0.29 |
Stock Price Statistics
The stock price has increased by 26.09% in the last 52 weeks. The beta is 0.63, so NovoCure's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | 26.09% |
| 50-Day Moving Average | 22.09 |
| 200-Day Moving Average | 20.59 |
| Relative Strength Index (RSI) | 35.51 |
| Average Volume (20 Days) | 927.79K |
Income Statement
In the last 12 months, NovoCure had revenue of 605.22M and earned -168.63M in profits. Earnings per share was -1.56.
| Revenue | 605.22M |
| Gross Profit | 468.04M |
| Operating Income | -170.5M |
| Net Income | -168.63M |
| EBITDA | -109.58M |
| EBIT | -170.5M |
| Earnings Per Share (EPS) | -1.56 |
Balance Sheet
The company has 163.77M in cash and 93.13M in debt, giving a net cash position of 70.64M.
| Cash & Cash Equivalents | 163.77M |
| Total Debt | 93.13M |
| Net Cash | 70.64M |
| Retained Earnings | -1.15B |
| Total Assets | 1.24B |
| Working Capital | 350.2M |
Cash Flow
In the last 12 months, operating cash flow was -26.37M and capital expenditures -42.85M, giving a free cash flow of -69.22M.
| Operating Cash Flow | -26.37M |
| Capital Expenditures | -42.85M |
| Free Cash Flow | -69.22M |
| FCF Per Share | -0.64 |
Margins
Gross margin is 77.33%, with operating and profit margins of -28.17% and -27.86%.
| Gross Margin | 77.33% |
| Operating Margin | -28.17% |
| Pretax Margin | -21.67% |
| Profit Margin | -27.86% |
| EBITDA Margin | -18.11% |
| EBIT Margin | -28.17% |
| FCF Margin | -11.44% |
Dividends & Yields
NVCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.45% |
| FCF Yield | -3.41% |
Analyst Forecast
The average price target for NVCR is $39, which is 111.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $39 |
| Price Target Difference | 111.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 4 |